Gap junctional intercellular communication (GJIC) has
Introduction
The microevolution of a normal cell into a metastatic cancer cell during carcinogenesis involves multiple genotypic and epigenetic changes (1, 2) . The loss of growth control, inability to contact inhibit or to terminally differentiate, and the ability to invade and metastasize (3, 4) are included in these changes. Gap junctional intercellular communication (GJIC*) has been hypothesized to play a role in growth control and differentiation (5, 6) . Most normal cells have the ability to perform GJIC (7), while dysfunctional or selective communication has been correlated with malignant and metastatic cells (8) (9) (10) (11) .
A family of evolutionarily conserved genes that code for the gap junction proteins, connexins, exists (12) (13) (14) and there is a tissue/cell type specific expression of these genes (15, 16) . Various chemicals, such as tumor promoters, hormones, growth factors and several oncogenes (17) , have been associated with the down-regulation of gap junctional intercellular communication at either the transcriptional, translational or post-translational levels (18, 19) . With the development of the concept of tumor suppressor genes (20) (21) (22) , as well as experimental evidence of specific chromosomes and genes having the ability to restore a non-tumorigenic phenotype to tumorigenic cells (23, 24) , it is possible to test the hypothesis that 'tumor suppressor' genes might be associated with the up-regulation of GJIC in non-communication tumor cells.
Using subtractive hybridization techniques, Lee et al. (24) demonstrated that one connexin gene (Cx26) was associated with the suppression of tumorigenicity in a tumorigenic mouse cell line. In addition, several laboratories have demonstrated that transfection of a gap junction gene into various tumorigenic cells helped to restore a normal phenotype and growth control in these cells (25) (26) (27) (28) (29) (30) (31) . Anti-sense cDNA to connexin43 in normal 10T1/2 prevented the suppression of transformed foci in co-cultures of transformed cells (32) . In addition, connexin 43 antisense oligonucleotides inhibited GJIC and enhanced growth in BALB/c3T3 cells (33) .
Several tumor suppressor genes have been identified on the human chromosome 11 for HeLa cells (34) (35) (36) , embryonal rhabdomyosarcoma (37), multiple endocrine neoplasia type 1 (38, 39) , insulinoma (40) , ataxia telangiectasia (41), cervical carcinoma (42) and breast carcinoma (43) , as well as rat liver epithelial tumors (44) . Previously, it had been shown that a tumorigenic clone of a HeLa cell, when fused with a human fibroblast, lost its tumorigenicity (34) . In this study, we have attempted to determine the status of GJIC in an independent tumorigenic HeLa clone (D98 AH.2), non-tumorigenic HeLa X normal fibroblast hybrid clones (CGL-1, CGL-2, ESH15, ESH15c1) and a tumorigenic segregant from the HeLafibroblast hybrid (CGL-3), using techniques to assess gap junction function, transcription of the connexin messages and presence of the connexin proteins.
Materials and methods

Cell lines and tissue cultures
The eight cell lines used in this study were as follows: GM00077, a normal human fibroblast line (NIGMS Human Genetic Mutant Cell Repository Institute for Medical Research, Camden, New Jersey) D98.AH2, an HGPRT -, 6-TG R variant of HeLa (20) , and HeLa, an independent clone separate from the D98.AH2 HeLa, obtained from the Michigan Department of Public Health Laboratories, Lansing, Michigan. CGL-1, CGL-2, ESH15 and ESH15c1, hybrids from D98.AH2 X GM00077 and CGL-3, a revertant from the aforementioned hybridization (35) . The fibroblast line was maintained in a modified Eagle's medium (MEM) (45) (Life Technologies/Gibco, Grand Island, New York), with 10% fetal calf serum (FCS) and (10 mg/l) phenol red. The remaining lines were grown in the same modified MEM with 7% FCS and no phenol red. The media were changed every 3 days. All cultures were maintained at 37°C, in a 5% CO 2 , humidified incubator.
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Gap junctional intercellular communication (GJIC) assays
Scrape loading/dye transfer (SL/DT), fluorescence re-distribution after photobleaching (GAP-FRAP) and microinjection-dye transfer assays were used to measure GJIC in the various cell lines. These techniques have been described in detail earlier (46, 47) and briefly, were carried out as follows.
SL/DT Technique
For an initial measurement of gap junctional intercellular communication (GJIC), all cell lines were scrape loaded and assessed for dye transfer (46) . Cultures were seeded in 35-mm dishes until a cell density of between 70 and 90% was obtained. Each dish was rinsed three times with Ca 2ϩ Mg 2ϩ phosphate buffered saline (PBS), incubated with 2 ml of 0.5 mg/ml (final concentration) Lucifer yellow (Molecular Probes, Eugene OR), scrape loaded and left undisturbed for 5 min. After removing the dye, cells were rinsed three more times and subsequently fixed in 4% formalin/Ca 2ϩ Mg 2ϩ PBS for 30 min prior to photography using a fluorescence microscope. In one of the experiments Lucifer yellow was combined with the high molecular weight dye Rhodamine dextran (Molecular Probes, Eugene, OR) (0.5 mg/ml) to visualize the primary loaded cells.
GAP-FRAP technique
This assay, originally described by Wade et al. (47) , and later modified by Barhoumi et al. (48) , was performed using an Ultima interactive laser cytometer equipped with an argon laser. Cells were cultured to a density of 80-90%, rinsed and incubated for 15 min with a photobleachable dye, 5,6-carboxyfluorescein diacetate (Molecular Probes, Eugene, OR), at a final concentration of 7 mg/ml. After labeling, the cells were rinsed to remove excess dye, and 2 ml of Ca 2ϩ Mg 2ϩ PBS were returned to the dish. Two to three areas were scanned per dish. Each area consisted of a control cell, which was left unbleached, and 5-9 cells were bleached using the 488-nm wavelength of the laser. The scanning consisted of five scans at 3-min increments for a total of 12 min. The amount of fluorescence recovery after photobleaching was quantitated and the values for each cell line were expressed as a percentage of the control: the human fibroblast cell line, GM00077.
Microinjection/dye transfer technique
Micro-injection was perform in Ca 2ϩ Mg 2ϩ PBS. Five to ten cells per dish were injected with 10% Lucifer yellow in 330 mM LiCl. Scanning was commenced within 5 s after injection using an Ultima with a vertically mounted IMT2-SYF microinjection attachment (Meridian Instruments, Okemos, MI). Each scan was~33 s in duration and 4-8 sequential scans were made of each injected cell.
Immunofluorescence detection of connexins
Cells were plated on either 4-or 8-well glass chamber slides to near 100% confluency. Each cell line was placed into 4-wells. After fixation in 5% acetic acid in methanol for 15 min at room temperature, the cells were incubated in PBS containing 10% heat inactivated goat serum, 0.3% gelatin and 0.05% Tween-20 to minimize non-specific binding. Connexin 43 labeling was done using either polyclonal Cx43 antibodies from E.Dupont as previously described (49, 50) or polyclonal Cx43 antibodies from Zymed Laboratories Inc. (South San Francisco, CA). As controls, one well was left in the blocking solution and for the polyclonal antibody from Dupont, one well was incubated with the peptide against the Cx43 antibody. The remaining two wells were incubated with the Cx43 antibodies. The reaction time was 1.5 h at room temperature followed by two 5-min rinses in 1% bovine serum albumin (BSA)/PBS. The secondary antibody was either fluorescein isothiocyanate (FITC) anti-rabbit immunoglobulin (IgG) or TRITC anti-rabbit IgG. In half of the experiments Hoechst (33258), a DNA dye, was used to help visualize the nucleus. The cells were rinsed with PBS and distilled water before addition of an anti-fade mounting medium (Aqua-Poly/Mount, Polysciences, Inc., Warrenting, PA). Coverslips were sealed and cells were scanned using the Ultima confocal analysis software (Meridian Instruments, Inc., Okemos, MI).
Reverse transcriptase-polymerase chain reaction (RT-PCR) detection of connexins
RNA was extracted using the TRI Reagent (Molecular Research Center, Inc., Cincinnati, OH) according to the manufacturer's protocol. Reverse transcription of 0.5-1 µg of total RNA was performed in a volume of 20 µl for 1 h at 37°C using 50 U M-MLV reverse transcriptase in 50 mM Tris-HCl (pH 8.3), 75 mM KCl, 10 mM dithiotheitol, 3 mM MgCl 2 , 25 U RNase inhibitor, 1 mM each of dATP, dGTP, dCTP, dTTP and 2.5 mM oligo (dt). The samples were heated to 95°C for 5 min to terminate the reverse transcription reaction
Polymerase chain reaction (PCR)
Reverse transcribed cDNA obtained from 0.5-1.0 µg of total RNA was added to a reaction mixture containing a final concentration of 10 mM Tris-HCl, pH 8.3, 50 mM KCl, 1.5 mM MgCl 2 , 0.2 mM each of dATP, dGTP, dCTP, dTTP and 0.5 mM each of 5Ј and 3Ј primer and 2.5 U Taq polymerase in a final reaction volume of 50 µl. The two primer sequences used were human Cx43: 5Ј-primer GCGTGAGGAAAGTACCAAAC, 3Ј-primer GGGCAACC-TTGAGTTCTTCC and human GAPDH: 5Ј-primer CCACCCATGGCAA-ATTCCATGGCA, 3Ј-primer TCTAGACGGCAGGTCAGGTCCACC. The mixture was heated to 95°C for 60 s in a Perkin-Elmer Thermo-Cycler. Amplification was performed in 35 sequential cycles at 95°C for 30 s, 63°C for 60 s and 72°C for 60 s followed by an incubation of 7 min at 72°C. The PCR products were analyzed on a 1.8% agarose gel that contained 10 mg/ml ethidium bromide in 0.5ϫ Tris-borate/EDTA buffer and the gels were photographed using Polaroid 655 film.
Western blot detection of connexin proteins
Proteins were extracted using the organic phase from the TRI-Extraction method (Molecular Research Center, Inc., Cincinnati, OH) according to the manufacturer's protocol. The protein content was determined with the DC protein assay (Bio-Rad Corp., Richmond, CA), after dilution of samples 1:5 with dd-H 2 O. Proteins were separated on 12.5% polyacrylamide gels and transferred to PDVF membranes at 20 V for 16 h. Cx43 was detected using an anti-connexin 43-specific monoclonal antibody (Zymed, San Francisco, CA), followed by either incubation with horseradish peroxidase (HRP)-conjugated secondary antibody and detection with the ECL chemiluminescent detection reagent (Amersham) or biotinylated anti-connexin 43, followed by treatment with streptavidin-AP in BCIP/NET as chromogens as previously described (51) .
Results
Measurement of GJIC by scrape loading/dye transfer
Typical results of the ability of each of the parental cell strains, cell lines, various non-tumorigenic hybrids and the tumorigenic revertant cell clone to exhibit functional gap junctions, by 749 scrape loading/dye transfer technique are shown in Figure 1 . The parental normal human fibroblast cell strain (GM00077) exhibited an ability to transfer Lucifer yellow, which indicates functional gap junctions ( Figure 1A) . Figure 1B and C show that the parental HeLa clone (D98.AH2) and an independent HeLa clone, which are tumorigenic in nude mice, were essentially negative for functional gap junctions as measured by the transfer of Lucifer yellow beyond the primary loaded line of cells. Four independently isolated human fibroblastHeLa (D98.AH2), hybrids that were previously shown to be non-tumorigenic in nude mice, showed significant ability to transfer Lucifer yellow, which indicates the presence of functional gap junctions (CGL-1, CGL-2, ESH15, ESH15c1, Figure 1D -G, respectively). In Figure 1H , the tumorigenic revertent, CGL-3, can be seen to have significantly reduced GJIC.
Measurement of GJIC by microinjection of Lucifer yellow dye
In order to validate the scrape loading/dye transfer results, the typical results of the microinjection technique of some of the same aforementioned parental cell strains and cell lines and their non-tumorigenic and tumorigenic derivative clones are shown in Figure 2 . The parental clone D98.AH2 was unable to transfer dye to neighboring cells (Figure 2A ). All the nontumorigenic clones (CGL-1, CGL-2, ESH15 and ESH15cl; Figure 2B -E) demonstrated their ability to transfer Lucifer yellow. The revertant tumorigenic HeLa-human fibroblast clone, CGL-3, showed no dye transfer, which suggests there were no functional gap junctions ( Figure 2F ).
Measurement of GJIC by fluorescent redistribution after photobleaching (GAP-FRAP)
Using the GAP-FRAP program and analysis software of an integrated laser cytometer to measure functional gap junctions, Figure 3 illustrates typical results of the analysis of GJIC by GAP-FRAP. Only one clone (ESH15cl) is illustrated ( Figure  3A -D: pre-bleach image, immediately after photobleaching image, and 3 and 12 min after photobleaching image, respectively), although GAP-FRAP data were generated on all of the clones. Figure 3E is the summary data of the four cells in Figure 3A -D. Again, the GAP-FRAP analyses verify and support the results of the two previous techniques. In Figure  4 , the results of the GAP-FRAP analyses of all the clones are shown to confirm the previous results of the scrape-loading/ dye transfer and microinjection techniques (Figures 1 and 2) .
Immunofluorescence staining for connexin 43
Indirect immunofluorescence staining of gap junctions in the control fibroblast, the independent parental HeLa clone, HeLahuman fibroblast hybrids and the revertant line were detected using anti-connexin 43 antibodies. Images shown in Figure 5 were obtained using the Meridian Ultima confocal scanning software. Figure 5A represents a typical area of connexin 43 antibody labeling for the normal human fibroblast line (GM00077). Figure 5B shows few to no plaques labeled in the independent HeLa clone. Figure 5C and D are the hybrids CGL-1 and CGl-2, respectively, both with fluorescent punctate staining typical for connexin 43 antibody labeling. Figure 5E represents a phase (transmission) scan that corresponds to the area in Figure 5D . Figure 5F is indicative of a no primary antibody control in a typical area of hybrid CGL-2. Figure 5G and H are ESH15 and ESH15c1, respectively, and both exhibit punctate labeling on their plasma membranes. The revertant CGL-3, a tumorigenic hybrid clone, shown in Figure 5I , represents an area that indicates the absence of connexin 43 plaques on the plasma membrane. Immunodetection of connexin 43 plaques on the plasma membrane lends further evidence to support the restoration of gap junctional intercellular communication in the hybrids as previously demonstrated using the techniques of scrape loading and dye transfer, microinjection and GAP-FRAP.
PCR detection of connexin expression
The data in Figure 6 show that Cx43 message was detected using the primer for human Cx43 in all lines assayed, however in the CGL-2 and CGL-3 cell lines, the level of message expressed was lower, in part because of the level of DNA loading when compared with the other lines run on the gel. No detection of Cx26 or 32 was detected in any of the human fibroblast, HeLa, or their non-tumorigenic or tumorigenic revertant clones (data not shown). In general, these data for the GJIC proficient clones, with the exception of the CGL-2 line, are consistent with the functional GJIC assays and with the immunofluorescence and Western blotting data. The CGL-2 line could be facilitating communication via a different connexin channel for which we did not assay. The low level detection of connexin 43 message in the non-communicating HeLa-human fibroblast revertant, CGL-3, is not inconsistent, since no protein or GJIC function was detected in this clone.
Western blot analyses of connexin 43
Results of experiments to determine the presence of the connexin 43 in the parental and derivative hybrid clones are shown in Figure 7 . It can clearly be seen that the antibodies to connexin 43 detected the proteins in normal human fibroblasts in a human kidney epithelial cell line (G401.2/ 6TG.1) and in the non-tumorigenic hybrids (CGL-1, CGL-2, ESH15, ESH15cl). No indication of the connexin 43 protein was seen in the parental HeLa, or in the revertant, tumorigenic hybrid CGL-3. These results also lend support to the techniques mentioned previously.
Discussion
The basic premise of these experiments was based on the hypothesis that normal cells have functional gap junctions and tumor cells have dysfunctional heterologous or homologous GJIC (8) (9) (10) (11) . Therefore, with the previously reported observations that a HeLa-human fibroblast hybrid cell line, formed from a non-tumorigenic human fibroblast cell strain and the tumorigenic HeLa cell line, was not tumorigenic in the nude mouse (34, 35) , it was predicted that the non-tumorigenic cell line should exhibit GJIC. The results of these experiments have shown that tumorigenic HeLa cells do not express detectable levels of Cx26, Cx32 or Cx43 protein and do not exhibit GJIC, as measured by scrape loading/dye transfer, microinjection and FRAP techniques. Although weak GJIC has been reported in some clones of HeLa cells (52, 53) , we were unable to detect any significant connexin protein or GJIC with any of the techniques used in this study, although Cx43 message was detected. The normal human fibroblast and 752 the non-tumorigenic hybrid cell lines all had functional gap junctions composed of Cx43, while the tumorigenic segregant CGL-3 did not have such functional junctions. A similar lack of homologous GJIC and Cx43 protein expression has been observed in a tumorigenic cell line derived from ultraviolet light (UVC)-irradiated non-tumorigenic HeLa X fibroblast cells, which demonstrated the same aggressive in vivo growth properties as CGL-3 (54; L.Redpath, pers. commun.).
Given that many cells derived from tumors, including HeLa cells, and carcinogen-induced and oncogene transfected neoplastic cells have been associated with defective GJIC (17, 19) , the results of this study seem to implicate the upregulation of GJIC with the expression of a tumor suppressor gene and the suppression of the tumorigenic phenotype (24) . Restoration of growth control and other non-tumorigenic phenotypes by the ameliorating effects of anti-tumor promoters, such as retinoids and carotenoids (55) (56) (57) (58) (59) (60) (61) (62) , green tea components (63, 64) , 1a,25-dihydroxyvitamin D3 (65) and lovastatin (66) , have been correlated with the up-regulation of GJIC. In addition, restoration of gap junction function in several tumorigenic cell types by transfection with a gap junction gene has been shown to be correlated with the restoration of growth control in these cells (25) (26) (27) (28) (29) (30) (31) . The demonstration that a gap junction message was found by subtractive hybridization between a tumorigenic and normal cell is also consistent with the hypothesis that GJIC is a necessary, if not sufficient, function for normal growth control (24) .
In the case of HeLa cells, the reason for the absence of GJIC and the gap junction messages could be because of the loss of specific chromosomes on which these genes are located: deletion or mutation of the connexin genes, or the transcriptional down-regulation of the connexin loci by methylation, or by some other mechanism. It seems highly likely that transcriptional regulation might be involved in HeLa cells, since there are several reports demonstrating that GJIC can be induced in HeLa cells. Conforti et al. (67) have shown that when HeLa cells are co-cultured in close contact with Friend erythroleukemia cells, gap junctions are induced in the HeLa cells. Also Sasaki et al. (68) have shown that HeLa cells, grown in spheroids and co-cultured with normal fibroblasts, have abundant gap junctions. Previous studies have demonstrated that tumorigenic suppression of HeLa cells could be brought about only by micro-cell transfer of a normal chromosome 11 (69) . Since the mapping of connexin 43 does not place Cx43 on chromosome 11 (70, 71) , the newly expressed Cx43 in the non-tumorigenic HeLa-human fibroblast hybrid could be the result of an induced transcribed gene in the HeLa genome caused by some regulatory gene residing on chromosome 11. If this is the case, identification of the 'tumor suppressor gene' on human chromosome 11 could have potentially important clinical therapeutic value for those cancer cells that have suppressed the Cx43 genes needed for growth control of those particular cell types.
Clearly, further experiments will be needed to identify the nature of the tumor suppressor gene(s) on human chromosome 11 in order to test these ideas.
